RC-3095 TFA

RC-3095 TFA is a selective bombesin / gastrin releasing peptide receptor ( GRPR ) antagonist RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice . In Vivo RC-3095 impairs aversive but not recognition memory in Wistar male rats . RC-3095 (0.3 mg/kg or 1 mg/kg; S.C.) shows anti-inflammatory effects in 2 experimental models of arthritis, collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA). Arthritic mice treated with RC-3095 show a significant reduction in the concentrations of IL-17, IL-1 , and TNF, and showed a diminished expression of GRPR. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Balb/c wild-type mice (weighing 18-25 gm) with AIA model; Male DBA/1J inbred mice (weighing 18-25 gm) with CIA modelDosage: 1 mg/kg for AIA studies; 0.3 mg/kg or 1 mg/kg for CIA studies Administration: Injected SC twice a day for a total of 2 or 10 days for AIA studies; Administered SC twice a day for 10 days after the onset of the disease for CIA studies Result: Reduced neutrophil migration, mechanical hy pernociception, and proteoglycan loss in mice with AIA; Led to a significant reduction in arthritis clinical scores and the severity of disease in the CIA model. Form:Solid IC50& Target:Bombesin receptor,GRPR

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet